SG11201706505PA - Stable liquid formulation for monoclonal antibodies - Google Patents
Stable liquid formulation for monoclonal antibodiesInfo
- Publication number
- SG11201706505PA SG11201706505PA SG11201706505PA SG11201706505PA SG11201706505PA SG 11201706505P A SG11201706505P A SG 11201706505PA SG 11201706505P A SG11201706505P A SG 11201706505PA SG 11201706505P A SG11201706505P A SG 11201706505PA SG 11201706505P A SG11201706505P A SG 11201706505PA
- Authority
- SG
- Singapore
- Prior art keywords
- monoclonal antibodies
- liquid formulation
- stable liquid
- stable
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305218 | 2015-02-13 | ||
| PCT/EP2016/053068 WO2016128564A1 (fr) | 2015-02-13 | 2016-02-12 | Formulation liquide stable pour des anticorps monoclonaux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706505PA true SG11201706505PA (en) | 2017-09-28 |
Family
ID=52589319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706505PA SG11201706505PA (en) | 2015-02-13 | 2016-02-12 | Stable liquid formulation for monoclonal antibodies |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180008707A1 (fr) |
| EP (1) | EP3256160A1 (fr) |
| JP (1) | JP2018507202A (fr) |
| KR (1) | KR20170117166A (fr) |
| CN (1) | CN107635581A (fr) |
| AU (1) | AU2016217806A1 (fr) |
| BR (1) | BR112017016636A2 (fr) |
| CA (1) | CA2976298A1 (fr) |
| MX (1) | MX2017010400A (fr) |
| RU (1) | RU2017131618A (fr) |
| SG (1) | SG11201706505PA (fr) |
| TW (1) | TW201632203A (fr) |
| WO (1) | WO2016128564A1 (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11420136B2 (en) | 2016-10-19 | 2022-08-23 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| SG11201811320YA (en) * | 2016-06-30 | 2019-01-30 | Celltrion Inc | Stable liquid pharmaceutical preparation |
| EP3558363A1 (fr) * | 2016-12-21 | 2019-10-30 | Amgen Inc. | Formulations d'anticorps anti-tnf alpha |
| EP3569224B1 (fr) * | 2017-01-11 | 2022-12-14 | Celltrion Inc. | Formule liquide stable |
| CN108686204A (zh) * | 2017-04-07 | 2018-10-23 | 浙江海正药业股份有限公司 | 包含组氨酸缓冲体系的英夫利西单抗组合物 |
| KR102439221B1 (ko) | 2017-12-14 | 2022-09-01 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| CN110092831B (zh) * | 2018-01-30 | 2022-05-20 | 北京睿诚海汇健康科技有限公司 | 植物作为宿主在表达阿达木抗体中的应用 |
| CN109280644B (zh) * | 2018-09-04 | 2023-02-17 | 四川安可瑞新材料技术有限公司 | 抗人IgG单克隆抗体、其杂交瘤细胞株及应用 |
| CN109266620B (zh) * | 2018-09-04 | 2023-01-10 | 四川安可瑞新材料技术有限公司 | 抗人IgG单克隆抗体、其杂交瘤细胞株及应用 |
| CN109112113B (zh) * | 2018-09-05 | 2023-01-10 | 四川安可瑞新材料技术有限公司 | 抗人IgG的单克隆抗体、杂交瘤细胞株、试剂盒及其应用 |
| CN109082413B (zh) * | 2018-09-18 | 2023-01-10 | 四川安可瑞新材料技术有限公司 | 抗人IgG单克隆抗体、其杂交瘤细胞株及应用 |
| CN109112114B (zh) * | 2018-09-18 | 2023-02-17 | 四川安可瑞新材料技术有限公司 | 抗人IgG单克隆抗体、其杂交瘤细胞株及应用 |
| KR20210096559A (ko) | 2018-11-27 | 2021-08-05 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 항IL-23p19 항체 및 이의 용도 |
| CN113474360A (zh) | 2019-02-18 | 2021-10-01 | 伊莱利利公司 | 治疗性抗体制剂 |
| MX2021010783A (es) | 2019-03-08 | 2021-09-30 | Boehringer Ingelheim Int | Formulaciones de anticuerpo anti-il-36r. |
| CN111686247B (zh) * | 2019-03-13 | 2022-07-29 | 苏州康乃德生物医药有限公司 | 包含人白介素-4受体α的抗体的液体组合物 |
| RU2754760C2 (ru) * | 2019-04-02 | 2021-09-07 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция анти-il17a антитела и ее применение |
| EP4119161A4 (fr) * | 2020-03-13 | 2024-05-15 | Samsung Bioepis Co., Ltd. | Composition pharmaceutique liquide présentant une stabilité améliorée |
| TWI802882B (zh) * | 2020-05-13 | 2023-05-21 | 大陸商信達生物制藥(蘇州)有限公司 | 包含抗IL-23p19抗體的製劑、其製備方法和用途 |
| JP7057954B2 (ja) * | 2020-09-03 | 2022-04-21 | 国立大学法人大阪大学 | 改善された保存安定性を有するタンパク質含有液体製剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EA201791717A1 (ru) * | 2012-09-07 | 2018-03-30 | Кохерус Байосайенсис, Инк. | Стабильные водные составы адалимумаба |
-
2016
- 2016-02-12 KR KR1020177025583A patent/KR20170117166A/ko unknown
- 2016-02-12 US US15/548,598 patent/US20180008707A1/en not_active Abandoned
- 2016-02-12 MX MX2017010400A patent/MX2017010400A/es unknown
- 2016-02-12 SG SG11201706505PA patent/SG11201706505PA/en unknown
- 2016-02-12 BR BR112017016636A patent/BR112017016636A2/pt not_active Application Discontinuation
- 2016-02-12 CA CA2976298A patent/CA2976298A1/fr not_active Abandoned
- 2016-02-12 JP JP2017542055A patent/JP2018507202A/ja active Pending
- 2016-02-12 CN CN201680021283.5A patent/CN107635581A/zh active Pending
- 2016-02-12 RU RU2017131618A patent/RU2017131618A/ru not_active Application Discontinuation
- 2016-02-12 AU AU2016217806A patent/AU2016217806A1/en not_active Abandoned
- 2016-02-12 WO PCT/EP2016/053068 patent/WO2016128564A1/fr active Application Filing
- 2016-02-12 EP EP16704440.3A patent/EP3256160A1/fr not_active Withdrawn
- 2016-02-15 TW TW105104382A patent/TW201632203A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2976298A1 (fr) | 2016-08-18 |
| CN107635581A (zh) | 2018-01-26 |
| WO2016128564A1 (fr) | 2016-08-18 |
| RU2017131618A (ru) | 2019-03-13 |
| US20180008707A1 (en) | 2018-01-11 |
| JP2018507202A (ja) | 2018-03-15 |
| KR20170117166A (ko) | 2017-10-20 |
| BR112017016636A2 (pt) | 2018-04-03 |
| TW201632203A (zh) | 2016-09-16 |
| MX2017010400A (es) | 2017-11-28 |
| EP3256160A1 (fr) | 2017-12-20 |
| AU2016217806A1 (en) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201706505PA (en) | Stable liquid formulation for monoclonal antibodies | |
| IL269499A (en) | Stable antibody formulation | |
| HK1249114A1 (zh) | 針對bcma的單克隆抗體 | |
| HK1257164A1 (zh) | 新型抗pd-l1抗體 | |
| HK1246324A1 (zh) | 抗pd-l1抗體 | |
| HK1257646A1 (zh) | 包含雙特異性抗體建構物之醫藥組合物 | |
| ZA201803874B (en) | Humanized anti-cd73 antibodies | |
| IL257062A (en) | New anti-pd-1 antibodies | |
| IL255727A (en) | Novel anti-pd-l1 antibodies | |
| HUE051700T2 (hu) | Anti-PD-1 antitestek | |
| HK1245813A1 (zh) | 抗-cgrp抗體製劑 | |
| IL250363A0 (en) | Stable formulation of anti-il-4r-alpha antibody | |
| HK1258375A1 (zh) | 人源化抗-cll-1抗體 | |
| IL248802A0 (en) | Antibody formulation | |
| IL256579A (en) | Human antibodies | |
| ZA201901865B (en) | Anti-pd-1 antibodies | |
| PL3371216T3 (pl) | Humanizowane przeciwciała anty-BAG3 | |
| EP3362093A4 (fr) | Anticorps monoclonaux neutralisant l'héparanase | |
| GB201511196D0 (en) | Monoclonal antibodies |